ZBTB44 and c14orf93 were differentially expressed, with ZBTB44 showing highest expression levels in one B-NHL and two myeloma cell lines and most frequent upregulation (5/9) in cell lines derived from T-cell malignancies. This evidence concerns the gene ZBTB44 and plasma cell myeloma.